FLT3 and acute myeloid leukemia: The ELN guidelines likewise stratify patients with FLT3-ITD AML into the “adverse risk” grouping but are somewhat more specific: only AML with an FLT3-ITD AR of greater than >0.5 is included, and only in the absence of mutant nucleophosmin (NPM1).